Stock SCS STEM CELLS SPIN S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Stem Cells Spin S.A.

Equities

SCS

PLSTCLS00013

Biotechnology & Medical Research

End-of-day quote Warsaw S.E.
Other stock markets
 18:00:00 2024-05-01 EDT 		5-day change 1st Jan Change
0.52 PLN 0.00% Intraday chart for Stem Cells Spin S.A. +4.84% +52.94%
02-14 Stem Cells Spin S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
02-14 Stem Cells Spin S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 4.657 10.75 23.56 78.54 29.56 11.57
Enterprise Value (EV) 1 11.38 11.99 24.69 79.51 29.89 11.97
P/E ratio 144 x -20.6 x -32.6 x 12,258 x -232 x 435 x
Yield - - - - - -
Capitalization / Revenue 10.7 x 20.5 x 40.5 x 293 x 56.2 x 46.6 x
EV / Revenue 26.1 x 22.9 x 42.4 x 296 x 56.8 x 48.2 x
EV / EBITDA 23.7 x 16.6 x -54.9 x 62.6 x 35.2 x 16.1 x
EV / FCF 392 x -1.4 x 9.91 x 92.1 x 12 x -6.87 x
FCF Yield 0.26% -71.5% 10.1% 1.09% 8.31% -14.6%
Price to Book 0.92 x 1.05 x 2.48 x 10.2 x 3.91 x 1.53 x
Nbr of stocks (in thousands) 12,937 41,337 41,337 41,337 41,337 41,337
Reference price 2 0.3600 0.2600 0.5700 1.900 0.7150 0.2800
Announcement Date 18-05-30 19-05-31 20-05-28 21-05-31 22-04-29 23-05-31
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.4356 0.5244 0.5822 0.2683 0.5259 0.2484
EBITDA 1 0.4793 0.7215 -0.4499 1.27 0.8499 0.7454
EBIT 1 0.0426 -0.4649 -0.7005 0.0417 -0.0768 -0.209
Operating Margin 9.77% -88.66% -120.33% 15.55% -14.6% -84.14%
Earnings before Tax (EBT) 1 0.0323 -0.5217 -0.7232 0.006409 -0.1274 0.0266
Net income 1 0.0323 -0.5217 -0.7232 0.006409 -0.1274 0.0266
Net margin 7.41% -99.5% -124.22% 2.39% -24.23% 10.72%
EPS 2 0.002493 -0.0126 -0.0175 0.000155 -0.003082 0.000643
Free Cash Flow 1 0.029 -8.567 2.492 0.8635 2.484 -1.743
FCF margin 6.66% -1,633.85% 428.03% 321.82% 472.36% -701.73%
FCF Conversion (EBITDA) 6.06% - - 67.99% 292.3% -
FCF Conversion (Net income) 89.98% - - 13,473.37% - -
Dividend per Share - - - - - -
Announcement Date 18-05-30 19-05-31 20-05-28 21-05-31 22-04-29 23-05-31
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 6.72 1.24 1.13 0.97 0.34 0.4
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 14.02 x 1.717 x -2.51 x 0.7669 x 0.3972 x 0.5371 x
Free Cash Flow 1 0.03 -8.57 2.49 0.86 2.48 -1.74
ROE (net income / shareholders' equity) 0.64% -6.83% -7.35% 0.08% -1.67% 0.35%
ROA (Net income/ Total Assets) 0.13% -1.44% -2.41% 0.17% -0.29% -0.82%
Assets 1 25.66 36.28 30.06 3.724 43.93 -3.249
Book Value Per Share 2 0.3900 0.2500 0.2300 0.1900 0.1800 0.1800
Cash Flow per Share 2 0 0 0 0 0.0100 0
Capex - 10.4 - - - -
Capex / Sales - 1,986.52% - - - -
Announcement Date 18-05-30 19-05-31 20-05-28 21-05-31 22-04-29 23-05-31
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
STEM CELLS SPIN S.A. Stock Stem Cells Spin S.A.
+52.94% 5.35M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.9B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.7B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SCS Stock
  4. Financials Stem Cells Spin S.A.